Physician profile
Kerry E Shaver
NPI 1285805952
$5,877.28
in general payments reported to CMS, 2019-2025
44 companies · $18.37 in 2025
The $18.37 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $614 · 2021: $1,531 · 2022: $1,462 · 2023: $1,318 · 2024: $58.37 · 2025: $18.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.05 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $981.36 | 2019-2023 | Ozempic, Rybelsus, Saxenda |
| Abbvie INC. | $980.02 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $336.30 | 2020-2023 | Trelegy Ellipta |
| Amgen INC. | $310.47 | 2019-2023 | Repatha, Otezla |
| Lilly USA, LLC | $303.03 | 2019-2024 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $263.41 | 2021-2023 | Nexletol |
| Pfizer INC. | $221.49 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $214.02 | 2019-2022 | |
| Astellas Pharma US INC | $198.58 | 2019-2023 | Myrbetriq, Veozah |
| Ironwood Pharmaceuticals, INC | $187.29 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.34 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $155.78 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $152.76 | 2020-2023 | |
| Allergan, INC. | $117.03 | 2019-2021 | |
| Abbott Laboratories | $100.12 | 2019 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.